NDAORALTABLET
Approved
Aug 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 26m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Leritine (anileridine hydrochloride) is an oral opioid analgesic approved in 1957 for pain management. It is a synthetic opioid agonist indicated for moderate to severe pain relief. The drug works by binding to opioid receptors in the central nervous system to reduce pain perception.
LOE Approaching
This legacy opioid faces moderate competitive pressure (30%) in a declining market, suggesting a small and focused brand team managing a mature asset.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Leritine offers limited career advancement due to its mature lifecycle stage and zero linked job openings. This role is best suited for professionals seeking experience in legacy product management or opioid risk mitigation in a declining franchise.
Brand ManagerCommercial Analyst
Worked on LERITINE at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.